Correction: Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study.

Drugs Real World Outcomes

Biogen IDEC, Clinical Research, Biosimilars, Maidenhead, UK.

Published: January 2025

Download full-text PDF	Source
http://dx.doi.org/10.1007/s40801-024-00477-4	DOI Listing

Publication Analysis

correction real-world

real-world evidence

evidence clinical

clinical outcomes

outcomes adalimumab

adalimumab biosimilar

biosimilar sb5

sb5 rheumatic

rheumatic gastrointestinal

gastrointestinal immune-mediated

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!